Physician profile
Jennifer Patel
NPI 1336381698
$12,118.29
in general payments reported to CMS, 2019-2025
31 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $657 · 2021: $962 · 2022: $952 · 2023: $5,995 · 2024: $1,271 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,195 · Consulting Fee: $3,645 · Travel and Lodging: $945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,194.71 |
| Consulting Fee | $3,645.00 |
| Travel and Lodging | $944.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $5,115.19 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $1,324.44 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,288.73 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,111.75 | 2021-2025 | Dupixent |
| Csl Behring | $757.56 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Genzyme Corporation | $565.17 | 2020-2025 | |
| Pfizer INC. | $431.52 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $311.34 | 2020-2025 | Cuvitru, Eohilia, Hyqvia |
| Novartis Pharmaceuticals Corporation | $171.31 | 2019-2025 | |
| Grifols USA, LLC | $141.71 | 2020-2024 | Prolastin-C Liquid, Xembify |
| Ars Pharmaceuticals Operations, INC. | $115.10 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $112.13 | 2021-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $73.83 | 2019-2020 | |
| Octapharma USA, INC. | $73.69 | 2023-2025 | Cutaquig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.40 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $54.06 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $48.50 | 2019 | |
| Amgen INC. | $46.33 | 2022-2025 | Tezspire |
| Pharming Healthcare, INC. | $45.19 | 2020-2025 | Ruconest |
| Bio Products Laboratory USA, INC. | $45.15 | 2019 | |
| Merck Sharp & Dohme LLC | $43.76 | 2022-2023 | |
| Kaleo, INC. | $28.35 | 2019-2020 | |
| X4 Pharmaceuticals, INC. | $25.52 | 2024 | Xolremdi |
| Uswm, LLC | $24.00 | 2021 | |
| Optinose US, INC. | $19.99 | 2024 | |
| Biocryst Pharmaceuticals, INC. | $18.23 | 2020 | |
| Abbvie INC. | $17.09 | 2024 | |
| Phadia US INC. | $16.61 | 2019 | |
| Hikma Pharmaceuticals USA | $15.40 | 2024 | Ryaltris |
| Ionis Pharmaceuticals, INC. | $14.19 | 2025 | Dawnzera |
| Cycle Pharmaceuticals INC | $8.05 | 2024 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.